Edwards Lifesciences Corporation(EW) Stock Research - Grey Stern Research

Edwards Lifesciences Corporation (EW) Stock Analysis

$65.37 (0.34%)

EW Financial Performance


Use the table below to view Edwards Lifesciences Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $65.15 -
52 Week Low $58.93 -
52 Week High $96.12 -
Market Cap $39.2 Billion 5/10
Gross Margin 79% 1/10
Profit Margin 26% 2/10
EBITDA margin 29% 2/10
Q2 - 2024 Revenue $1.4 Billion 6/10
Q2 - 2024 Earnings $366.3 Million 4/10
Q2 - 2024 Free Cash Flow $286.1 Million 5/10
Trailing 4 Quarters Revenue $6.0 Billion 5/10
Trailing 4 Quarters Earnings $1.5 Billion 5/10
Quarterly Earnings Growth 19% 5/10
Annual Earnings Growth 11% 8/10
Quarterly Revenue Growth -9% 10/10
Annual Revenue Growth 2% 7/10
Cash On Hand $1.6 Billion 4/10
Short Term Debt $21.5 Million 10/10
Long Term Debt $597.3 Million 8/10

Edwards Lifesciences Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Edwards Lifesciences Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 26.64 9/10
PS 6.54 4/10
PB 5.23 6/10
PC 23.81 8/10
Liabilities to Equity 0.35 10/10
ROA 0.15 1/10
ROE 0.20 3/10
Current Ratio 3.89 1/10
Quick Ratio 0.77 1/10
Long Term Debt to Equity 0.08 9/10
Debt to Equity 0.09 9/10
Burn Rate -4.89 6/10
Cash to Cap 0.04 1/10
CCR 0.78 5/10
EV to EBITDA 94.71 6/10
EV to Revenue 6.38 5/10

Company Details

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

CEO: Mr. Michael Mussallem

Website: https://www.edwards.com

Address: 1 Edwards Way Irvine, CALIFORNIA

Exchange: New York Stock Exchange

Industry: Medical Devices

Edwards Lifesciences Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Edwards Lifesciences Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Boston Scientific Corporation BSX $124.4 Billion
Abbott Laboratories ABT $197.7 Billion
Medtronic plc MDT $114.3 Billion
Zimmer Biomet Holdings, Inc. ZBH $21.5 Billion
Tandem Diabetes Care, Inc. TNDM $2.7 Billion
DexCom, Inc. DXCM $26.9 Billion
Stryker Corporation SYK $135.3 Billion
Insulet Corporation PODD $16.3 Billion
Align Technology, Inc. ALGN $17.8 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
EW Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 1.4 Billion $366.3 Million
Q1 2024 $ 1.6 Billion $351.9 Million
Q4 2023 $ 1.5 Billion $369.9 Million
Q3 2023 $ 1.5 Billion $384.9 Million
Q2 2023 $ 1.5 Billion $307.1 Million
Q1 2023 $ 1.5 Billion $340.5 Million
Q4 2022 $ 1.3 Billion $398.4 Million
Q3 2022 $ 1.3 Billion $343.5 Million

View All

EW Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $1.6 Billion $10.1 Billion $693.0 Million $7.5 Billion
Q1 2024 $1.2 Billion $9.7 Billion $699.2 Million $7.2 Billion
Q4 2023 $1.1 Billion $9.4 Billion $694.9 Million $6.7 Billion
Q3 2023 $1.4 Billion $9.4 Billion $691.1 Million $6.7 Billion
Q2 2023 $1.0 Billion $9.0 Billion $684.5 Million $6.4 Billion
Q1 2023 $872.5 Million $8.7 Billion $687.8 Million $6.0 Billion
Q4 2022 $769.0 Million $8.3 Billion $691.3 Million $5.8 Billion
Q3 2022 $1.2 Billion $8.6 Billion $686.8 Million $6.2 Billion

View All

EW Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $286.1 Million -$85.4 Million $419.8 Million
Q1 2024 -$138.8 Million -$85.3 Million $81.0 Million
Q4 2023 $800,000 $0 $800,000
Q3 2023 $356.2 Million -$55.3 Million $366.4 Million
Q2 2023 $1.0 Million $0 $1.0 Million
Q1 2023 $252.6 Million -$61.5 Million $103.8 Million
Q4 2022 $193.7 Million -$89.1 Million -$479.1 Million
Q3 2022 $250.0 Million -$59.9 Million $48.8 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions